Every 8-K that Heartbeam, Inc. (BEAT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BEAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEAT filings page.
HeartBeam, Inc. entered into an At-The-Market Equity Offering Sales Agreement with Titan Partners Securities LLC as sales agent. Under this agreement, HeartBeam may sell from time to time up to $25,000,000 of common stock through at-the-market offerings under its existing shelf Registration Statement on Form S-3. The company filed a prospectus supplement dated August 14, 2026 covering these sales. Titan Partners will receive a commission of up to 3% of the gross sales price per share and has been provided customary indemnification and contribution rights.
HeartBeam, Inc. filed an amendment to update terms related to the departure of Robert P. Eno, confirming that a Separation Agreement and an Advisory Agreement were executed on July 30, 2026.
Under the Separation Agreement, Mr. Eno receives a lump sum cash payment of $300,000, equal to nine months of base salary, in exchange for a release of claims and continued compliance with restrictive covenants. He is eligible to serve as a non-employee advisor under the Advisory Agreement, with a one-time $1,000 advisory retainer. All of his outstanding stock options and restricted stock units fully vest, and the post-termination exercise period for each option is extended until the earlier of December 31, 2027 or the option’s original expiration. HeartBeam will also reimburse up to nine months of COBRA premiums.
HeartBeam, Inc. reported the results of its July 31, 2026 annual stockholder meeting held via live webcast. As of the June 5, 2026 record date, 55,506,835 shares of common stock were outstanding and entitled to vote, and 29,050,272 votes, or 52.34% of outstanding votes, were represented, constituting a quorum.
Stockholders elected all seven director nominees to one-year terms, with each receiving over 10 million votes in favor and approximately 0.9–1.3 million votes against, plus broker non-votes. They also approved the ratification of CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026, with 28,612,850 votes for and 173,008 against.
A proposal to amend the 2022 Equity Incentive Plan to increase authorized shares by 3,000,000 shares did not receive stockholder approval, drawing 3,957,529 votes for, 7,816,794 against, 41,929 abstentions and 17,234,020 broker non-votes.
HeartBeam, Inc. has received a Nasdaq notice that its common stock is out of compliance with the exchange’s $1.00 minimum bid price requirement, after trading below this level for 30 consecutive business days.
The company has 180 calendar days, until December 28, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days. A second 180-day period may be available if other Nasdaq listing standards, including market value of publicly held shares, are met.
The notice does not immediately affect HeartBeam’s Nasdaq Capital Market listing, but failure to regain compliance could ultimately lead to delisting, subject to possible appeal to a Nasdaq hearings panel.
HeartBeam, Inc. announced a strategic reorganization and leadership transition centered on accelerating global adoption of its ambulatory ECG signal platform and improving capital efficiency. Chief Executive Officer and director Robert P. Eno will depart effective June 30, 2026, and is expected to move into a consulting role under his existing employment agreement, subject to a release of claims.
Founder and President Branislav Vajdic, Ph.D. will serve as principal executive officer effective July 1, 2026, while operations are aligned around focused implementation teams led by Dr. Vajdic and Executive Chairman Rich Ferrari. Director Mark Strome resigned from the Board on June 18, 2026; both his resignation and Mr. Eno’s departure are stated as not due to disputes or disagreements with the company.
The company highlights that its 3D ambulatory ECG platform, including 3D signal capture and 12‑lead ECG synthesis, has received FDA clearance for arrhythmia assessment, and it plans to continue clinical studies to expand its technology for heart attack and other cardiac conditions while targeting a meaningfully lower cost structure.
HeartBeam, Inc. reported new compensation arrangements for its President, Founder and Director, Dr. Branislav Vajdic. On June 15, 2026, the board approved a performance-based restricted stock unit (PRSU) award covering 2,800,000 restricted stock units under the 2022 Equity Incentive Plan.
The PRSUs vest only if both performance and service conditions are met. Performance milestones tied to operational, software, product-development and clinical study goals must be achieved within a period that ends on the earlier of one year from grant or just before a first Change in Control. Service-based vesting occurs in three equal annual installments over three years, with acceleration provisions upon a Change in Control or certain qualifying terminations. HeartBeam also entered into a Transaction Bonus Agreement with Dr. Vajdic, providing a bonus upon a Qualifying Change in Control based on achieving specified market capitalization and per-share price thresholds, paid generally in the same form as consideration to stockholders.
HeartBeam, Inc. entered an underwriting agreement with Titan Partners Group for an underwritten public offering of 12,500,000 shares of common stock at a public price of $0.80 per share, raising approximately $10.0 million in gross proceeds upon closing.
The underwriter will purchase shares at $0.744 per share and holds a 30‑day option to buy up to 1,875,000 additional shares to cover over‑allotments. HeartBeam will also issue underwriter warrants equal to 5% of the total shares sold, exercisable immediately for five years.
The company and its officers and directors agreed to a 75‑day lock‑up on specified securities. Net proceeds are intended to support commercialization of its FDA‑cleared 12‑lead synthesized ECG system, development of its extended‑wear patch and heart attack detection initiatives, enhancement of AI capabilities, and working capital and general corporate purposes.
HeartBeam, Inc. reported that on November 20, 2025 it received a Not Substantially Equivalent (NSE) letter from the U.S. Food and Drug Administration regarding its 510(k) application for its 12-Lead Electrocardiogram (ECG) Synthesis Software. An NSE letter means the FDA did not find the device substantially equivalent to a predicate device under this submission. The company stated that it stands behind its clinical data and plans to work with the FDA to reach a resolution. HeartBeam also noted it is evaluating the launch of its novel 3D ECG system, which previously received FDA 510(k) clearance in December 2024.